SCHEMBL24309478

SCHEMBL24309478

Cc1cccc(C)c1-c1cc(OCCC(C)(C)O)nc(NSc2cnn(C)c2)n1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IRAK1 P51617 3/20 0.34
▸ ACVR2A P27037 2/20 0.34
▸ TGFBR2 P37173 2/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ IRAK4 Q9NWZ3 2/20 0.33
▸ MAP4K1 Q92918 4/20 0.32
▸ FFAR1 O14842 1/20 0.32
▸ PIK3CD O00329 1/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ PIM1 P11309 2/20 0.31
▸ HTR7 P34969 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ FGFR1 P11362 1/20 0.30
▸ FGFR2 P21802 1/20 0.30
▸ FGFR4 P22455 1/20 0.30
▸ FGFR3 P22607 1/20 0.30
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310780 0.87 ACVR2A (0.36) IRAK1ACVR2ATGFBR2CYP2C9KCNH2
SCHEMBL29566657 0.81 PIK3CG (0.41) IRAK1ACVR2ATGFBR2CYP2C9KCNH2
SCHEMBL26806504 0.81 PIK3CG (0.41) IRAK1ACVR2ATGFBR2CYP2C9KCNH2
SCHEMBL24309553 0.81 MAP4K1 (0.31) MAP4K1
SCHEMBL24310079 0.81 ACVR2A (0.37) IRAK1ACVR2ATGFBR2CYP2C9KCNH2
SCHEMBL24309990 0.80 CYP19A1 (0.36) ACVR2ATGFBR2CYP2C9KCNH2FFAR1
SCHEMBL24310347 0.79 GPR39 (0.39) CYP2C9
SCHEMBL24309575 0.79 NPC1 (0.33) —
SCHEMBL24310627 0.79 WNT1 (0.33) IRAK4MAP4K1PIM1
SCHEMBL24309556 0.78 MAP4K1 (0.35) MAP4K1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback